The stock of Fibrocell Science Inc (NASDAQ:FCSC) hit a new 52-week high and has GBX 1.01 target or 6.00% above today’s GBX 0.95 share price. The 7 months bullish chart indicates low risk for the GBX 45.03 million company. The 1-year high was reported on Nov, 23 by Barchart.com. If the GBX 1.01 price target is reached, the company will be worth GBX 2.70M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock last traded at $0.95 per share. It is down 69.35% since April 21, 2016 and is downtrending. It has underperformed by 74.68% the S&P500.
Fibrocell Science Inc (NASDAQ:FCSC) Ratings Coverage
Out of 3 analysts covering Fibrocell Science (NASDAQ:FCSC), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $14.0 is the highest target while $14 is the lowest. The $14 average target is 1373.68% above today’s ($0.95) stock price. Fibrocell Science has been the topic of 3 analyst reports since September 28, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Roth Capital on Tuesday, December 22. As per Monday, September 28, the company rating was downgraded by Wedbush. The stock of Fibrocell Science Inc (NASDAQ:FCSC) has “Buy” rating given on Tuesday, December 22 by TH Capital.
More recent Fibrocell Science Inc (NASDAQ:FCSC) news were published by: Marketwatch.com which released: “Fibrocell Science stock price target cut to $4 from $6 at Wedbush Securities” on April 17, 2011. Also Quotes.Wsj.com published the news titled: “News Fibrocell Science Inc.FCSC” on September 08, 2011. Globenewswire.com‘s news article titled: “Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief …” with publication date: March 18, 2015 was also an interesting one.
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The company has a market cap of $45.03 million. The Firm is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. It currently has negative earnings. The Company’s product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.